Soleus Capital Master Fund, L.P. 13D and 13G filings for Adverum Biotechnologies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 08:06 am Sale |
2022-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
Soleus Capital Master Fund, L.P. | 0 0.000% |
-498,279 (Position Closed) |
Filing |
| 2022-09-02 10:18 am Purchase |
2022-08-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
Soleus Capital Master Fund, L.P. | 498,279 5.000% |
498,279 (New Position) |
Filing |